Full Text

Turn on search term navigation

© 2020. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

[...]it seems the probiotics could be considered as at least a complementary treatment for different types of malignancies. Based on different reports, the outbreak of H. pylori infection is respectively ~90%, 58.4%, and 51% in some regions of Iran, Saudi Arabia, and Turkey.3-6 Unfortunately, the treatment of H. pylori infection still remains unsuccessful, in large part because of its complex biology and adaptive mechanisms.7 Currently, antibiotic therapy is the only approach for controlling the infection, in which clarithromycin, amoxicillin, or metronidazole can somewhat inhibit the H. pylori infection.8 However, it is believed that the triple antibiotic therapy may be failed in 10%-23% of patients.9 In reality, the emergence of point mutations in the H. pylori genome can lead to the resistance of the bacterium to the clarithromycin and metronidazole.10 Accordingly, exploring new approaches for controlling or treatment of the H. pylori infection are intensely demanded.1 Although a vaccine that induces a humoral immune response and Th2 cells will be a suitable platform to inhibit the H. pylori bacteria, there is still no effective vaccine(s) available to control the infection.11 Various groups in the world work to construct efficient vaccine(s) against the H. pylori infection and several of these deigned constructs are being evaluated in different clinical trial phases.12,13 More recently, probiotics have been considered as a novel tool for controlling H. pylori infections.1,14 Based on the definition of the Food and Agriculture Organization (FAO) and the World Health Organization (WHO), probiotics are live microorganisms that can confer beneficial health effects on their hosts if they are administered in suitable amounts.15 Probiotics such as lactobacilli are capable of inhibiting H. pylori by various immunological and nonimmunological mechanisms.16 In general, probiotics can inhibit the proliferation of the bacterium through competing with H. pylori for host surface receptors, and subsequently disrupt its adhesion to the epithelial cells.17 Moreover, probiotics can counteract with spiral bacteria by secreting some antibacterial compounds including lactic acid, bacteriocins, hydrogen peroxide, short-chain fatty acids, and antibiotic-like substances such as reuterin and reutericyclin.18 More importantly, lactic acid is probably effective on the H. pylori growth via lowering the pH and inhibiting its urease enzyme.19 It should be noted that probiotics can modify the immunologic responses including neutrophils, lymphocytes, plasma cells, and macrophages and then trigger the inflammatory responses against H. pylori.20 Thus, the levels of pro-inflammatory cytokines like IL-1ß, IL-2, IL-6, IL-8, and tumor necrosis factor a are significantly increased in the gastric mucosa. [...]a significant level of the Bax protein is accumulated in the H. pylori-infected cells.25 Moreover, several studies have confirmed different effects of H. pylori on the other apoptosis-involved genes such as AKT, Tp53, and IL-6.26-28 Here, we evaluated the anti-apoptotic effects of the locally isolated probiotic bacterium L. plantarum on the AGS in the presence of H. pylori. [...]the treated cells were subjected to different biological analyses.31 RNA extraction and RT-PCR Total RNA was extracted from the treated AGS and Huvec cell lines using the TRIzol® reagent (Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer's instructions.

Details

Title
Lactobacillus plantarum induces apoptosis in gastric cancer cells via modulation of signaling pathways in Helicobacter pylori
Author
Maleki-Kakelar, Hadi 1 ; Dehghani, Jaber 1 ; Barzegari, Abolfazl 1 ; Barar, Jaleh 1 ; Shirmohamadi, Masoud 2 ; Sadeghi, Javid; Omidi, Yadollah

 Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran 
 Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 
Pages
65-72
Publication year
2020
Publication date
2020
Publisher
Tabriz University of Medical Sciences
ISSN
22285652
e-ISSN
22285660
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2405312840
Copyright
© 2020. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.